CGRP potentiates excitatory transmission to the circular muscle of guinea-pig colon.
We aimed to assess whether calcitonin gene-related peptide (CGRP) can modulate the release of tachykinins which are the main nonadrenergic noncholinergic (NANC) excitatory transmitters to the circular muscle of the guinea-pig proximal colon. In organ bath experiments, electrical field stimulation (EFS) in the presence of atropine (1 microM) and guanethidine (3 microM) evoked twitch phasic NANC contractions which were abolished by the combined administration of tachykinin NK1 and NK2 receptor antagonists. Human alphaCGRP (CGRP, 1-100 nM) produced a concentration-dependent potentiation of the amplitude of the NANC contractions induced by EFS while salmon calcitonin (up to 1 microM) had no effect. The potentiating effect of CGRP was unaffected by in vitro capsaicin pretreatment (10 microM for 15 min), peptidase inhibitors (captopril, bestatin and thiorphan, 1 microM each), apamin (0.3 microM) plus L-nitroarginine (L-NOARG, 100 microM) and by the CGRP1 receptor antagonist, the C-terminal fragment CGRP(8-37) (1 microM). The NK2 receptor antagonist MEN 10627 which, when administered alone, had only a partial inhibitory effect on the amplitude of NANC twitches, concentration-dependently (10 nM-1 microM) inhibited the potentiating effect of CGRP. CGRP (1-100 nM) produced a concentration-dependent potentiation of the atropine-sensitive cholinergic contractions evoked by EFS in the presence of guanethidine and of tachykinin NK1 and NK2 receptor antagonists. Similar to the effect of CGRP, application of capsaicin (0.1-1 microM) potentiated the amplitude of the NANC contraction to EFS, an effect undergoing complete desensitization upon a second application of the drug. CGRP (0.1 microM) did not affect the contractile action of a submaximally effective concentration of neurokinin A (2 nM) while it inhibited that induced by substance P (2 nM). In sucrose gap, single pulse EFS in the presence of atropine (1 microM) and guanethidine (3 microM) induced an inhibitory junction potential (i.j.p.) and a small excitatory junction potential (e.j.p.). CGRP (0.1 microM) produced membrane hyperpolarization and relaxation without affecting i.j.p. amplitude but concomitantly increased the e.j.p. amplitude to induce a contraction in correspondence to each electrical pulse. In the presence of the NK1 receptor antagonist, GR 82334 (3 microM), the membrane hyperpolarization and relaxation produced by CGRP and the EFS-evoked i.j.p. were unaffected, while the potentiating effect of CGRP on the EFS-evoked NANC e.j.p. and the corresponding contraction were abolished. We conclude that, in addition to the previously characterized direct smooth muscle relaxant action via CGRP1 receptors (Maggi et al. Regulatory Peptides 61, 27-36, 1996), CGRP also induces a remarkable potentiation of excitatory neurotransmission to the circular muscle of the guinea-pig colon via CGRP2 receptors. The latter effect, documented in this study, is evidenced on both the atropine-sensitive and the atropine-resistant (tachykinin-mediated) components of excitatory transmission: this effect does not involve mediator(s) release from capsaicin-sensitive primary afferent nerves, nor inhibition of peptide degradation or modulation of NANC inhibitory transmission.
Maggi
C A
CA
Pharmacology Department, Menarini Ricerche, Florence, Italy.
Giuliani
S
S
Santicioli
P
P
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology* / Q000502:physiology; D003106:Colon / Q000187:drug effects / Q000294:innervation*; D004558:Electric Stimulation; D006145:Guanethidine / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation*; D015288:Neurokinin A / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000502:physiology; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D013373:Substance P / Q000494:pharmacology; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology; D015320:Tachykinins / Q000378:metabolism
D018377:Neurotransmitter Agents; D011950:Receptors, Cholinergic; D015320:Tachykinins; D013373:Substance P; D001285:Atropine; D015288:Neurokinin A; D015740:Calcitonin Gene-Related Peptide; D006145:Guanethidine